| A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension (NCT07660796) | Hanmi Pharmaceutical Company Limited | 2026-07-06 |
| Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus (NCT07527650) | Hanmi Pharmaceutical Company Limited | 2026-05-18 |
| A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin (NCT07379333) | Hanmi Pharmaceutical Company Limited | 2026-04-13 |
| Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma (NCT07449754) | Hanmi Pharmaceutical Company Limited | 2026-02-12 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers (NCT07297693) | Hanmi Pharmaceutical Company Limited | 2025-12-19 |
| Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus (NCT07205900) | Hanmi Pharmaceutical Company Limited | 2025-12-02 |
| A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants (NCT07219589) | Hanmi Pharmaceutical Company Limited | 2025-11-06 |
| Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT06724016) | Hanmi Pharmaceutical Company Limited | 2024-12-11 |
| A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients (NCT06595004) | Hanmi Pharmaceutical Company Limited | 2024-11-22 |
| A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers (NCT06518122) | Hanmi Pharmaceutical Company Limited | 2024-09-01 |
| A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. (NCT06481098) | Hanmi Pharmaceutical Company Limited | 2024-05-28 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions (NCT06357910) | Hanmi Pharmaceutical Company Limited | 2024-05-17 |
| A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients (NCT06174766) | Hanmi Pharmaceutical Company Limited | 2024-05-10 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers (NCT06346184) | Hanmi Pharmaceutical Company Limited | 2024-05-02 |
| A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension (NCT06438172) | Hanmi Pharmaceutical Company Limited | 2024-03-25 |
| A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus (NCT06174779) | Hanmi Pharmaceutical Company Limited | 2024-01-03 |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors (NCT06234397) | Hanmi Pharmaceutical Company Limited | 2023-12-28 |
| A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers (NCT05862090) | Hanmi Pharmaceutical Company Limited | 2023-04-05 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers (NCT05737082) | Hanmi Pharmaceutical Company Limited | 2023-03-30 |
| A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer (NCT05656092) | Hanmi Pharmaceutical Company Limited | 2023-03-06 |
| A Study to Evaluate the PK, Safety and Tolerability of HCP1803. (NCT05723549) | Hanmi Pharmaceutical Company Limited | 2023-02-02 |
| Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors (NCT05598151) | Hanmi Pharmaceutical Company Limited | 2023-01-11 |
| Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function (NCT05711381) | Hanmi Pharmaceutical Company Limited | 2022-12-02 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions (NCT05548543) | Hanmi Pharmaceutical Company Limited | 2022-10-17 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers (NCT05548387) | Hanmi Pharmaceutical Company Limited | 2022-09-02 |
| A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients (NCT05450601) | Hanmi Pharmaceutical Company Limited | 2022-09-01 |
| A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203 (NCT05481307) | Hanmi Pharmaceutical Company Limited | 2022-08-02 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers. (NCT05407220) | Hanmi Pharmaceutical Company Limited | 2022-06-29 |
| A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension (NCT05362110) | Hanmi Pharmaceutical Company Limited | 2022-05-16 |
| HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (NCT04732416) | Hanmi Pharmaceutical Company Limited | 2022-05-05 |
| Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects (NCT04775706) | Hanmi Pharmaceutical Company Limited | 2022-03-03 |
| Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients (NCT05199129) | Hanmi Pharmaceutical Company Limited | 2021-11-17 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers (NCT05155995) | Hanmi Pharmaceutical Company Limited | 2021-09-28 |
| Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (NCT05024721) | Hanmi Pharmaceutical Company Limited | 2021-08-09 |
| A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects. (NCT05191563) | Hanmi Pharmaceutical Company Limited | 2021-07-31 |
| Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers (NCT04975711) | Hanmi Pharmaceutical Company Limited | 2021-07-12 |
| A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008 (NCT04946903) | Hanmi Pharmaceutical Company Limited | 2021-06-10 |
| FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer (NCT04768686) | Hanmi Pharmaceutical Company Limited | 2021-05-18 |
| Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers (NCT04967014) | Hanmi Pharmaceutical Company Limited | 2021-05-06 |
| A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension (NCT04959305) | Hanmi Pharmaceutical Company Limited | 2021-04-22 |
| The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers (NCT04764201) | Hanmi Pharmaceutical Company Limited | 2021-01-16 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903 (NCT04762407) | Hanmi Pharmaceutical Company Limited | 2020-11-20 |
| Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients (NCT04820907) | Hanmi Pharmaceutical Company Limited | 2020-10-27 |
| Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers (NCT04324905) | Hanmi Pharmaceutical Company Limited | 2020-04-29 |
| An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia (NCT05555238) | Hanmi Pharmaceutical Company Limited | 2020-01-16 |
| Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects (NCT04204629) | Hanmi Pharmaceutical Company Limited | 2020-01-13 |
| Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects (NCT04076293) | Hanmi Pharmaceutical Company Limited | 2019-10-08 |
| Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities (NCT04167553) | Hanmi Pharmaceutical Company Limited | 2019-08-30 |
| A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia (NCT04074551) | Hanmi Pharmaceutical Company Limited | 2019-07-16 |
| An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia (NCT05422677) | Hanmi Pharmaceutical Company Limited | 2019-07-15 |
| A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects (NCT04081857) | Hanmi Pharmaceutical Company Limited | 2019-06-03 |
| An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding (NCT05487560) | Hanmi Pharmaceutical Company Limited | 2019-04-18 |
| Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects (NCT03882112) | Hanmi Pharmaceutical Company Limited | 2019-04-17 |
| A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension (NCT03897868) | Hanmi Pharmaceutical Company Limited | 2019-03-21 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects (NCT03826641) | Hanmi Pharmaceutical Company Limited | 2019-02-01 |
| A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects. (NCT04322266) | Hanmi Pharmaceutical Company Limited | 2018-12-21 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects. (NCT04084197) | Hanmi Pharmaceutical Company Limited | 2018-12-19 |
| Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) (NCT04252963) | Hanmi Pharmaceutical Company Limited | 2018-11-02 |
| Efficacy and Safety of HIP1601 Capsule (NCT04080726) | Hanmi Pharmaceutical Company Limited | 2018-10-25 |
| Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis (NCT04324918) | Hanmi Pharmaceutical Company Limited | 2018-10-23 |
| Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease (NCT03666351) | Hanmi Pharmaceutical Company Limited | 2018-10-18 |
| A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects (NCT04032782) | Hanmi Pharmaceutical Company Limited | 2018-10-02 |
| A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects. (NCT04081844) | Hanmi Pharmaceutical Company Limited | 2018-05-03 |
| An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet (NCT05450575) | Hanmi Pharmaceutical Company Limited | 2018-04-17 |
| A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide) (NCT03374241) | Hanmi Pharmaceutical Company Limited | 2018-04-04 |
| Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI (NCT04510415) | Hanmi Pharmaceutical Company Limited | 2018-03-29 |
| An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet (NCT05462535) | Hanmi Pharmaceutical Company Limited | 2018-02-26 |
| Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations (NCT03372850) | Hanmi Pharmaceutical Company Limited | 2018-02-15 |
| Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise (NCT03353350) | Hanmi Pharmaceutical Company Limited | 2017-12-05 |
| Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap. (NCT04654702) | Hanmi Pharmaceutical Company Limited | 2017-11-17 |
| An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol (NCT04788290) | Hanmi Pharmaceutical Company Limited | 2017-11-06 |
| Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus (NCT03332836) | Hanmi Pharmaceutical Company Limited | 2017-10-25 |
| Molar Potency Study of HM12460A in Healthy Subjects (NCT03330314) | Hanmi Pharmaceutical Company Limited | 2017-10-24 |